INDSWFTLAB.NS Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 май 2024 @ 13:00):

Stats
Объем за сегодня	937 047
Средний объем	1.04M
Рыночная капитализация	6.63B
EPS	INR0 ( 2024-02-12 )
Дата следующего отчета о доходах	( INR0 ) 2024-05-13
Last Dividend	INR1.000 ( 2011-09-20 )
Next Dividend	INR0 ( N/A )
P/E	15.27
ATR14	INR0.226 (0.20%)

Объем Корреляция

Длинно: -0.05 (neutral)

Кратко: -0.38 (neutral)

Signal:(29.663) Neutral

Ind-Swift Laboratories Корреляция

10 Самые положительные корреляции
PVP.NS	0.827
ICICIPHARM.NS	0.813
KIMS.NS	0.811

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Ind-Swift Laboratories Корреляция - Валюта/Сырье

-0.25
( neutral )

-0.17
( neutral )

-0.14
( neutral )

-0.28
( neutral )

0.13
( neutral )

0.28
( neutral )

Ind-Swift Laboratories Финансовые показатели

Annual	2022
Выручка:	INR12.07B
Валовая прибыль:	INR5.52B (45.70 %)
EPS:	INR8.06

FY	2022
Выручка:	INR12.07B
Валовая прибыль:	INR5.52B (45.70 %)
EPS:	INR8.06

FY	2022
Выручка:	INR10.39B
Валовая прибыль:	INR4.28B (41.20 %)
EPS:	INR-0.360

FY	2021
Выручка:	INR8.91B
Валовая прибыль:	INR3.61B (40.51 %)
EPS:	INR-0.530

Financial Reports:

No articles found.

Ind-Swift Laboratories Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Ind-Swift Laboratories Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 1.760 - low (50.00%) | Divividend Growth Potential Score: 2.47 - No dividend growth expected in the near future

Information

First Dividend	INR1.000	2004-09-23
Last Dividend	INR1.000	2011-09-20
Next Dividend	INR0	N/A
Payout Date	2011-10-26
Next Payout Date	N/A
# dividends	8	--
Total Paid Out	INR9.00	--
Avg. Dividend % Per Year	0.00%	--
Score	1.21	--
Div. Sustainability Score	1.760
Div.Growth Potential Score	2.47
Div. Directional Score	2.12	--

Next Divdend (Est)
(2024-06-27)

INR0 Estimate 0.00 %

Dividend Stability

0.02 Very Bad

Dividend Score

1.21

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR0	0.00%
2019	INR0	0.00%
2020	INR0	0.00%
2021	INR0	0.00%
2022	INR0	0.00%
2023	INR0	0.00%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
RBLBANK.NS	Dividend Junior	2023-08-18	Sporadic	8	0.25%
KOVAI.NS	Dividend Junior	2023-08-10	Annually	4	0.17%
EXIDEIND.NS	Dividend Junior	2023-08-01	Annually	22	0.76%
AMIORG.NS	Dividend Junior	2023-09-18	Annually	3	0.15%
TALBROAUTO.NS	Dividend Junior	2023-09-15	Annually	18	0.48%
NGIL.NS	No Dividend Player	2023-09-21	Annually	4	0.08%
IGPL.NS	Dividend Junior	2023-08-17	Sporadic	18	1.12%
CHEMFAB.NS	Dividend Junior	2023-08-22	Sporadic	7	0.32%
SAKSOFT.NS	Dividend Junior	2023-08-07	Semi-Annually	20	0.56%
LUMAXIND.NS	Dividend Junior	2023-08-10	Annually	23	1.26%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0362	1.500	9.28	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.0612	1.500	-0.431	-0.647	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	2.56	1.000	-0.163	-0.163	[3 - 30]
operatingCashFlowPerShareTTM	16.90	2.00	4.37	8.74	[0 - 30]
freeCashFlowPerShareTTM	16.90	2.00	1.552	3.10	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.476	1.000	5.40	5.40	[0.2 - 0.8]
operatingProfitMarginTTM	0.181	1.000	8.37	8.37	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				1.760

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	15.47	1.000	8.54	0	[1 - 100]
returnOnEquityTTM	0.0612	2.50	-0.277	-0.647	[0.1 - 1.5]
freeCashFlowPerShareTTM	16.90	2.00	4.37	3.10	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	16.90	2.00	4.37	8.74	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.482	1.500	-0.118	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0838	1.000	-0.406	0	[0.1 - 0.5]
Total Score				2.47

Ind-Swift Laboratories

Ind-Swift Laboratories Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) in India. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, antimigraine, Parkinson disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antiprotozoal, anticholinergic, sedative, hypnotic, alcohol abstinence, and antineoplastic, as well as various products for ADHD symptoms. It provides reference standards and impurities for acamprosate calcium, anastrozole, aripiprazole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clopidogrel bisulphate, Clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide. The company also offers early and late phase drug development, process research and development, contract and API manufacturing, and custom chemicals and synthesis; and analytical development, regulatory support, chemistry, impurity profiling, isolation, discovery, identification and characterization, and project management services. It also exports its products. Ind-Swift Laboratories Limited was founded in 1995 and is based in Manimajra, India.